|Dr. Deborah Dunsire M.D.||Pres & CEO||52.4M||N/A||1962|
|Mr. Jacob Tolstrup||Exec. VP of Commercial Operations & Chief Commercial Officer||6.5M||N/A||1972|
|Mr. Lars Bang||Exec. VP of Product Devel. & Supply||6.7M||N/A||1962|
|Dr. Per Johan Luthman||Exec. VP of R&D||6.6M||N/A||1959|
|Mr. Joerg Hornstein||CFO & Exec. VP of Corp. Functions||N/A||N/A||1977|
|Dr. Tarek Samad Ph.D.||Sr. VP & Head of Research||N/A||N/A||N/A|
|Mr. Palle Holm Olesen||Chief Specialist & VP of Investor Relations||N/A||N/A||N/A|
|Ms. Elise Hauge||Exec. VP of People & Communication||N/A||N/A||1967|
|Mr. Ole Chrintz||Sr. VP of International Markets||N/A||N/A||1958|
|Mr. Keld Flintholm Jorgensen||Exec. VP of Corp. Strategy & Bus. Devel.||N/A||N/A||1971|
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.
H. Lundbeck A/S’s ISS governance QualityScore as of 1 October 2022 is 3. The pillar scores are Audit: 3; Board: 4; Shareholder rights: 1; Compensation: 6.